$IONM
Assure Holdings Corp. Stock $ionm

$ionm Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000155837022003471 Filed on March 14, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021
Revenue	$9.659M	$8.546M	$29.19M
YoY Change	61.96%	115.81%	728.38%
Cost Of Revenue	$4.362M	$4.254M	$14.32M
YoY Change	53.05%	90.59%	80.97%
Gross Profit	$5.297M	$4.292M	$14.87M
YoY Change	70.1%	147.95%	-438.97%
Gross Profit Margin	54.84%	50.22%	50.95%
Selling, General & Admin	$4.864M	$3.427M	$15.89M
YoY Change	17.29%	48.61%	47.09%
% of Gross Profit	91.83%	79.85%	106.81%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$515.0K	$192.0K	$1.114M
YoY Change	-49.21%	-23.2%	9.86%
% of Gross Profit	9.72%	4.47%	7.49%
Operating Expenses	$5.013M	$3.720M	$17.00M
YoY Change	14.14%	45.6%	43.89%
Operating Profit	$284.0K	$572.0K	-$2.127M
YoY Change	-122.22%	-169.42%	-86.87%
Interest Expense	-$662.0K	-$296.0K	-$1.412M
YoY Change	141.61%	-43.08%	-43.66%
% of Operating Profit	-233.1%	-51.75%
Other Income/Expense, Net	-$17.00K	-$323.0K	-$1.458M
YoY Change	-101.36%	-37.88%	43.22%
Pretax Income	-$395.0K	$249.0K	-$3.585M
YoY Change	246.49%	-118.53%	-79.18%
Income Tax	-$86.00K	$158.0K	-$829.0K
% Of Pretax Income		63.45%
Net Earnings	-$309.0K	$91.00K	-$2.756M
YoY Change	-4.92%	-109.31%	-81.67%
Net Earnings / Revenue	-3.2%	1.06%	-9.44%
Basic Earnings Per Share		$0.01	-$0.24
Diluted Earnings Per Share	-$25.09K	$0.01	-$0.24
COMMON SHARES
Basic Shares Outstanding	11.84M	11.84M	11.73M
Diluted Shares Outstanding		15.72M	11.73M

Balance Sheet

Concept	2021 Q4	2021 Q3	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.020M	$918.0K	$4.020M
YoY Change	-8.34%	512.0%	-8.34%
Cash & Equivalents	$4.020M	$918.0K
Short-Term Investments
Other Short-Term Assets	$151.0K	$104.0K	$151.0K
YoY Change	-75.57%	-76.36%	-46.83%
Inventory
Prepaid Expenses
Receivables	$27.81M	$22.68M	$27.81M
Other Receivables	$6.022M	$5.884M	$6.022M
Total Short-Term Assets	$38.00M	$29.59M	$38.00M
YoY Change	52.16%	56.22%	52.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$85.00K	$109.0K	$1.784M
YoY Change	-76.12%	-87.02%	63.97%
Goodwill	$4.448M	$4.448M
YoY Change	53.38%
Intangibles	$3.649M	$3.763M
YoY Change	-11.32%
Long-Term Investments	$525.0K	$638.0K	$525.0K
YoY Change	-13.65%	30.2%	-13.65%
Other Assets		$144.0K
YoY Change
Total Long-Term Assets	$10.41M	$9.979M	$10.41M
YoY Change	20.05%	18.52%	20.05%
TOTAL ASSETS
Total Short-Term Assets	$38.00M	$29.59M	$38.00M
Total Long-Term Assets	$10.41M	$9.979M	$10.41M
Total Assets	$48.41M	$39.57M	$48.41M
YoY Change	43.89%	44.62%	43.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.194M	$2.069M	$2.194M
YoY Change	-23.55%	66.85%	-23.58%
Accrued Expenses	$153.0K	$579.0K	$153.0K
YoY Change	23.39%		23.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$515.0K	$306.0K	$1.370M
YoY Change	-87.44%	-96.4%	-69.54%
Total Short-Term Liabilities	$3.717M	$2.964M	$3.717M
YoY Change	-51.01%	-70.12%	-51.01%
LONG-TERM LIABILITIES
Long-Term Debt	$13.17M	$10.45M	$14.27M
YoY Change	485.03%	186.33%	372.08%
Other Long-Term Liabilities	$864.0K	$580.0K	$864.0K
YoY Change	-73.2%	-96.5%	-73.2%
Total Long-Term Liabilities	$13.17M	$10.45M	$15.14M
YoY Change	485.03%	-48.31%	142.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.717M	$2.964M	$3.717M
Total Long-Term Liabilities	$13.17M	$10.45M	$15.14M
Total Liabilities	$19.45M	$15.31M	$19.45M
YoY Change	34.77%	-49.7%	34.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$14.44M	-$14.14M
YoY Change	23.58%
Common Stock	$13.00K	$12.00K
YoY Change	18.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$28.96M	$24.26M	$28.96M
YoY Change
Total Liabilities & Shareholders Equity	$48.41M	$39.57M	$48.41M
YoY Change	43.89%	44.62%	43.89%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021
OPERATING ACTIVITIES
Net Income	-$309.0K	$91.00K	-$2.756M
YoY Change	-4.92%	-109.31%	-81.67%
Depreciation, Depletion And Amortization	$515.0K	$192.0K	$1.114M
YoY Change	-49.21%	-23.2%	9.86%
Cash From Operating Activities	-$4.021M	-$3.091M	-$13.37M
YoY Change	58.74%	87.33%	320.01%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$107.0K	$30.00K	$1.000K
YoY Change	-98.51%	-102.78%	-100.01%
Cash From Investing Activities	-$107.0K	$30.00K	$1.000K
YoY Change	-98.57%	-102.78%	-100.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.062M
YoY Change			-47.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.230M	19.00K	13.01M
YoY Change	-49.64%	-99.27%	-13.34%
NET CHANGE
Cash From Operating Activities	-4.021M	-3.091M	-13.37M
Cash From Investing Activities	-107.0K	30.00K	1.000K
Cash From Financing Activities	7.230M	19.00K	13.01M
Net Change In Cash	3.102M	-3.042M	-366.0K
YoY Change	-28.31%	2435.0%	-108.46%
FREE CASH FLOW
Cash From Operating Activities	-$4.021M	-$3.091M	-$13.37M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$4.021M	-$3.091M	-$13.37M
YoY Change	81.62%	87.33%	281.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2
CY2020Q2	ionm	Number Of Warrants Issued Per Unit NumberOfWarrantsIssuedPerUnit	0.5
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	743000
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	608000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3649000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4115000
CY2021Q4	us-gaap	Goodwill Goodwill	4448000
CY2020Q4	us-gaap	Goodwill Goodwill	2857000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1082000
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1209000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1114000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1014000
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001798270
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11275788
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12918866
CY2021Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://www.AssureHoldingsCorp.com/20211231#LeaseLiabilitiesCurrent http://www.AssureHoldingsCorp.com/20211231#LeaseLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.AssureHoldingsCorp.com/20211231#LeaseLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://www.AssureHoldingsCorp.com/20211231#LeaseLiabilitiesCurrent http://www.AssureHoldingsCorp.com/20211231#LeaseLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.AssureHoldingsCorp.com/20211231#LeaseLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.AssureHoldingsCorp.com/20211231#LeaseLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.AssureHoldingsCorp.com/20211231#LeaseLiabilitiesNoncurrent
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11275788
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12918866
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-40785
CY2021	dei	Entity Registrant Name EntityRegistrantName	ASSURE HOLDINGS CORP.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2726719
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	7887 E. Belleview Ave., Suite 500
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Englewood
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80237
CY2021	dei	City Area Code CityAreaCode	720
CY2021	dei	Local Phone Number LocalPhoneNumber	287-3093
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	IONM
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	16000000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12919666
CY2021	dei	Auditor Name AuditorName	Baker Tilly US, LLP
CY2021	dei	Auditor Location AuditorLocation	Irvine, California
CY2021Q4	us-gaap	Cash Cash	4020000
CY2020Q4	us-gaap	Cash Cash	4386000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27810000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14965000
CY2021Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	136000
CY2020Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	150000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	151000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	618000
CY2021Q4	us-gaap	Due From Affiliates DueFromAffiliates	5886000
CY2020Q4	us-gaap	Due From Affiliates DueFromAffiliates	4856000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	38003000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	24975000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	525000
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	608000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	85000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	356000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	956000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	124000
CY2021Q4	us-gaap	Assets Assets	48409000
CY2020Q4	us-gaap	Assets Assets	33643000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2194000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2871000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	515000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4100000
CY2021Q4	ionm	Lease Liabilities Current LeaseLiabilitiesCurrent	702000
CY2020Q4	ionm	Lease Liabilities Current LeaseLiabilitiesCurrent	521000
CY2021Q4	ionm	Acquisition Liabilities Current AcquisitionLiabilitiesCurrent	306000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	96000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3717000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7588000
CY2021Q4	ionm	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	1482000
CY2020Q4	ionm	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	772000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13169000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2251000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	459000
CY2020Q4	ionm	Provision For Acquisition Share Issuance ProvisionForAcquisitionShareIssuance	540000
CY2021Q4	ionm	Provision For Fair Value Of Stock Options ProvisionForFairValueOfStockOptions	25000
CY2020Q4	ionm	Provision For Fair Value Of Stock Options ProvisionForFairValueOfStockOptions	16000
CY2020Q4	ionm	Provision For Performance Share Issuance ProvisionForPerformanceShareIssuance	2668000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	601000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	599000
CY2021Q4	us-gaap	Liabilities Liabilities	19453000
CY2020Q4	us-gaap	Liabilities Liabilities	14434000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	180000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12918866
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11275788
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	13000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	11000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43387000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30886000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14444000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11688000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	28956000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	19209000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48409000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33643000
CY2021	ionm	Revenue Revenue Adjustments From Contract With Customer Excluding Assessed Tax RevenueRevenueAdjustmentsFromContractWithCustomerExcludingAssessedTax	29192000
CY2020	ionm	Revenue Revenue Adjustments From Contract With Customer Excluding Assessed Tax RevenueRevenueAdjustmentsFromContractWithCustomerExcludingAssessedTax	3524000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	14318000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	7912000
CY2021	us-gaap	Gross Profit GrossProfit	14874000
CY2020	us-gaap	Gross Profit GrossProfit	-4388000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14805000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9592000
CY2021	us-gaap	Operating Expenses OperatingExpenses	17001000
CY2020	us-gaap	Operating Expenses OperatingExpenses	11815000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2127000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-16203000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	225000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1194000
CY2020	ionm	Gain On Forgiveness Of Paycheck Protection Program Loan GainOnForgivenessOfPaycheckProtectionProgramLoan	1211000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	188000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-46000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	89000
CY2021	us-gaap	Accretion Expense AccretionExpense	556000
CY2020	us-gaap	Accretion Expense AccretionExpense	782000
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1081000
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	530000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1458000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1018000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3585000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17221000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-829000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2185000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2756000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15036000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.07
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.07
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11725422
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7246625
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11725422
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7246625
CY2021	us-gaap	Profit Loss ProfitLoss	-2756000
CY2020	us-gaap	Profit Loss ProfitLoss	-15036000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	225000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1194000
CY2021	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	1913000
CY2020	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	548000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1114000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1014000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	93000
CY2021	ionm	Provision For Stock Option Fair Value ProvisionForStockOptionFairValue	9000
CY2020	ionm	Provision For Stock Option Fair Value ProvisionForStockOptionFairValue	-50000
CY2020	ionm	Gain On Forgiveness Of Paycheck Protection Program Loan GainOnForgivenessOfPaycheckProtectionProgramLoan	1211000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	188000
CY2021	us-gaap	Accretion Expense AccretionExpense	556000
CY2020	us-gaap	Accretion Expense AccretionExpense	782000
CY2020	ionm	Settlement Of Payables SettlementOfPayables	40000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1561000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10845000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15898000
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-133000
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	116000
CY2021	ionm	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-48000
CY2020	ionm	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	301000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-920000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1494000
CY2021	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	1071000
CY2020	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	2573000
CY2021	ionm	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-500000
CY2020	ionm	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	192000
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	846000
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	388000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	76000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-66000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13373000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3184000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	319000
CY2021	ionm	Repayment Of Acquired Debt Classified As Investing Activity RepaymentOfAcquiredDebtClassifiedAsInvestingActivity	307000
CY2020	ionm	Repayment Of Acquired Debt Classified As Investing Activity RepaymentOfAcquiredDebtClassifiedAsInvestingActivity	7736000
CY2021	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	308000
CY2020	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	558000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7497000
CY2021	ionm	Proceeds From Stock Options And Warrants Exercises ProceedsFromStockOptionsAndWarrantsExercises	19000
CY2020	ionm	Proceeds From Stock Options And Warrants Exercises ProceedsFromStockOptionsAndWarrantsExercises	19000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5062000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9611000
CY2020	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	1978000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1418000
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1665000
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1211000
CY2020	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	2122000
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1000000
CY2021	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	10360000
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	4100000
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2485000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13006000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15008000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-366000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	4327000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4386000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4020000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4386000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	973000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	498000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	16000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	55000
CY2021	ionm	Purchase Of Equipment With Finance Leases PurchaseOfEquipmentWithFinanceLeases	431000
CY2021	us-gaap	Settlement Of Asset Retirement Obligations Through Noncash Payments Amount SettlementOfAssetRetirementObligationsThroughNoncashPaymentsAmount	2668000
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	540000
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	60000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	10065000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	19000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9615000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	548000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	961000
CY2020	ionm	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Tax AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtTax	-388000
CY2020	ionm	Adjustments To Additional Paid In Capital Fair Value Of Finders Warrants AdjustmentsToAdditionalPaidInCapitalFairValueOfFindersWarrants	46000
CY2020	ionm	Settlement Of Performance Share Liability Value SettlementOfPerformanceShareLiabilityValue	13339000
CY2020	ionm	Stock Issued During Period Value Settlement Of Payables StockIssuedDuringPeriodValueSettlementOfPayables	40000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15036000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	19209000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	19000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5062000
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2815000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1913000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	60000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	1203000
CY2021	ionm	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Tax AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtTax	-862000
CY2021	ionm	Settlement Of Performance Share Liability Value SettlementOfPerformanceShareLiabilityValue	2293000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2756000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	28956000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">1. NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Assure Holdings Corp. (“Assure” or the “Company”), through its two indirect wholly-owned subsidiaries, Assure Neuromonitoring, LLC (“Neuromonitoring”) and Assure Networks, LLC (“Networks”), provides technical and professional intraoperative neuromonitoring (“IONM”) surgical support services primarily associated with spine and head surgeries. These services have been recognized as the standard of care by hospitals and surgeons for risk mitigation. Assure Holdings, Inc., a wholly-owned subsidiary, employs most of the corporate employees and performs various corporate services on behalf of the consolidated Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Neuromonitoring employs technologists who utilize technical equipment and their technical training to monitor EEG and EMG signals during surgical procedures and to pre-emptively notify the underlying surgeon of any nerve related issues that are identified. The technologists perform their services in the operating room during the surgeries. The technologists are certified by a third party accreditation agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Networks performs similar support services as Neuromonitoring except that these services are provided by third party contracted neurologists or certified readers. The support services provided by Networks occurs at the same time and for the same surgeries as the support services provided by the Neuromonitoring technologist, except that they typically occur at an offsite location.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company was originally incorporated in Colorado on November 7, 2016. In conjunction with a reverse merger, the Company was redomiciled in Nevada on May 16, 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Neuromonitoring was formed on August 25, 2015 in Colorado and currently has multiple wholly-owned subsidiaries. The Company’s services are sold in the United States, directly through the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Networks was formed on November 7, 2016 in Colorado and holds varying ownerships interests in numerous Provider Network Entities (“PEs”), which are professional IONM entities. These entities are accounted for under the equity method of accounting. Additionally, Networks manages other PEs that Networks does not have an ownership interest and charges those PEs a management fee. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;">COVID-19</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our business and results of operations have been, and continues to be, adversely affected by the global COVID-19 pandemic and related events and we expect its impact to continue. The impact to date has included periods of significant volatility in various markets and industries, including the healthcare industry. The volatility has had, and we anticipate it will continue to have, an adverse effect on our customers and on our business, financial condition and results of operations, and may result in an impairment of our long-lived assets, including goodwill, increased credit losses and impairments of investments in other companies. In particular, the healthcare industry, hospitals and providers of elective procedures have been and may continue to be impacted by the pandemic and/or other events beyond our control, and further volatility could have an additional negative impact on these industries, customers, and our business. In addition, the COVID-19 pandemic and, to a lesser extent, the impact on other industries, including automotive, electronics and real estate, increased fuel costs, U.S. restrictions on trade, and transitory inflation have impacted and may continue to impact the financial conditions of our customers and the patients they serve.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:10.8pt;text-align:justify;background:#ffffff;margin:0pt;">In addition, actions by United States federal, state and foreign governments to address the COVID-19 pandemic, including travel bans, stay-at-home orders and school, business and entertainment venue closures, also had and may continue to have a significant adverse effect on the markets in which we conduct our businesses. COVID-19 poses the risk that our workforce, suppliers, and other partners may be prevented from conducting normal business activities for an extended period of time, including due to shutdowns or stay-at-home orders that may be requested or mandated by governmental authorities. We have implemented policies to allow our employees to work remotely as a result of the pandemic as we reviewed processes related to workplace safety, including social distancing and sanitation practices recommended by the Centers for Disease Control and Prevention (CDC). The COVID-19 pandemic could also cause delays in acquiring new </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">customers and executing renewals and could also impact our business as consumer behavior changes in response to the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:10.8pt;text-align:justify;background:#ffffff;margin:0pt;">Since the start of the second quarter of 2021, there has been increased availability and administration of vaccines against COVID-19, as well as an easing of restrictions on social, business, travel, and government activities and functions, including healthcare and elective surgeries, and we have experienced a gradual resumption of economic activities in our industries. On the other hand, infection rates continue to fluctuate in various regions and new strains of the virus, including the Delta variant, remain a risk, which may give rise to implementation of restrictions in the geographic areas that we serve. In addition, there are ongoing global impacts resulting from the pandemic, including disruption of the supply chains, product shortages, increased delivery costs, increased governmental regulation, strains on healthcare systems, and delays in shipments, product development, technology launches and facility access. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:10.8pt;text-align:justify;background:#ffffff;margin:0pt;">We have been closely monitoring the COVID-19 pandemic and its impact on our business, including legislation to mitigate the impact of COVID-19 such as the Coronavirus Aid, Relief, and Economic Security (CARES) Act which was enacted in March 2020, and the American Rescue Plan Act of 2021 which was enacted in March 2021. Although a significant portion of our anticipated revenue for 2021 is derived from fixed-fee and minimum-guarantee arrangements, primarily from large, well-capitalized customers which we believe somewhat mitigates the risks to our business, our per-unit and variable-fee based revenue will continue to be susceptible to the volatility, supply chain disruptions, microchip shortages and potential market downturns induced by the COVID-19 pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:10.8pt;text-align:justify;background:#ffffff;margin:0pt;">The full extent of the future impact of the COVID-19 pandemic on the Company’s operational and financial performance is uncertain and will depend on many factors outside the Company’s control, including, without limitation, the timing, extent, trajectory and duration of the pandemic; the availability, distribution and effectiveness of vaccines; the spread of new variants of COVID-19; the continued and renewed imposition of protective public safety measures; the impact of COVID-19 on integration of acquisitions, expansion plans, implementation of telemedicine, restrictions on elective procedures, delays in payor remittance and increased regulations; and the impact of the pandemic on the global economy and demand for consumer products. Although we are unable to predict the full impact and duration of the COVID-19 pandemic on our business, we are actively managing our financial expenditures in response to continued uncertainty. Further discussion of the potential impacts on our business from the COVID-19 pandemic is provided under Part I, Item 1A – Risk Factors of the Form 10-K<span style="color:#231f20;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:10.8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#231f20;visibility:hidden;"></span></p>
CY2021	ionm	Number Of Subsidiaries NumberOfSubsidiaries	2
CY2021	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	During September 2021, the Company effectuated a five-for-one reverse stock split. All share, stock option and warrant information has been retroactively adjusted to reflect the stock split. See Note 11 for additional discussion.
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The accounting estimates and assumptions that require management’s most significant, difficult, and subjective judgment include the recognition and measurement of patient service fees, net, hospital, management and other revenue, the collectability of accounts receivable, the fair value measurements of goodwill and intangible assets, the assessment of the recoverability of goodwill, the assessment of useful lives and recoverability of intangible assets and long-lived assets, recognition and measurement of current and deferred income tax assets and liabilities, the assessment of unrecognized tax benefits, the valuation and recognition of stock-based compensation expense and business combinations, among others. Actual results experienced by the Company may differ from management’s estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Revisions to accounting estimates are recognized in the period in which the estimate is revised and also in future periods when the revision affects both current and future periods. Significant assumptions, judgments, and estimates that management has made at the end of the reporting period that could result in a material adjustment to the carrying amounts of assets and liabilities in the event that actual results differ from assumptions made, relate to, but are not limited to, the following: patient service fees, net; hospital, management, and other revenue; accounts receivable; and due to/from related parties.</p>
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	459000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	ionm	Revenue Revenue Adjustments From Contract With Customer Excluding Assessed Tax RevenueRevenueAdjustmentsFromContractWithCustomerExcludingAssessedTax	29192000
CY2020	ionm	Revenue Revenue Adjustments From Contract With Customer Excluding Assessed Tax RevenueRevenueAdjustmentsFromContractWithCustomerExcludingAssessedTax	3524000
CY2020Q2	ionm	Reduction To Earnings Loss From Equity Method Investments ReductionToEarningsLossFromEquityMethodInvestments	900000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27810000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14965000
CY2021Q4	ionm	Right Of Use Asset RightOfUseAsset	1699000
CY2020Q4	ionm	Right Of Use Asset RightOfUseAsset	732000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	2000000.0
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	1300000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	700000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	374000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	344000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	85000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	356000
CY2021	us-gaap	Depreciation Depreciation	102000
CY2020	us-gaap	Depreciation Depreciation	172000
CY2021Q4	ionm	Operating Lease Number Of Sub Leases OperatingLeaseNumberOfSubLeases	2
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.10
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	956000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	124000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	743000
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	608000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	124000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	212000
CY2020	ionm	Operating Lease Interest Payment On Liability OperatingLeaseInterestPaymentOnLiability	15000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	124000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	227000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	381000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	371000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	67000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	64000
CY2021	ionm	Finance Lease Cost FinanceLeaseCost	448000
CY2020	ionm	Finance Lease Cost FinanceLeaseCost	435000
CY2021	us-gaap	Lease Cost LeaseCost	572000
CY2020	us-gaap	Lease Cost LeaseCost	662000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	210000
CY2021Q4	ionm	Accrued Salaries And Benefits AccruedSalariesAndBenefits	552000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.069
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.079
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	1400000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	513000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	295000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	623000
CY2021Q4	ionm	Operating And Finance Lease Liability To Be Paid Year One OperatingAndFinanceLeaseLiabilityToBePaidYearOne	918000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	303000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	306000
CY2021Q4	ionm	Operating And Finance Lease Liability To Be Paid Year Two OperatingAndFinanceLeaseLiabilityToBePaidYearTwo	609000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	328000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	239000
CY2021Q4	ionm	Operating And Finance Lease Liability To Be Paid Year Three OperatingAndFinanceLeaseLiabilityToBePaidYearThree	567000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	278000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	148000
CY2021Q4	ionm	Operating And Finance Lease Liability To Be Paid Year Four OperatingAndFinanceLeaseLiabilityToBePaidYearFour	426000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	23000
CY2021Q4	ionm	Operating And Finance Lease Liability To Be Paid Year Five OperatingAndFinanceLeaseLiabilityToBePaidYearFive	23000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1204000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1339000
CY2021Q4	ionm	Operating And Finance Lease Liability Payment Due OperatingAndFinanceLeaseLiabilityPaymentDue	2543000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	212000
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	147000
CY2021Q4	ionm	Operating And Finance Lease Liability Undiscounted Excess Amount OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount	359000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	992000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1192000
CY2021Q4	ionm	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	2184000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	153000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	549000
CY2021Q4	ionm	Lease Liability Current LeaseLiabilityCurrent	702000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	839000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	643000
CY2021Q4	ionm	Lease Liability Noncurrent LeaseLiabilityNoncurrent	1482000
CY2020Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	500000
CY2021Q2	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	328000
CY2020Q2	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	800000
CY2021Q2	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	1700000
CY2021Q2	ionm	Business Combination Consideration Payable In Cash Including Interest BusinessCombinationConsiderationPayableInCashIncludingInterest	818750
CY2021Q2	ionm	Business Combination Number Of Equal Installments BusinessCombinationNumberOfEqualInstallments	36
CY2021Q2	ionm	Business Combination Additional Consideration Founders Bonus Payable BusinessCombinationAdditionalConsiderationFoundersBonusPayable	50000
CY2021Q4	us-gaap	Goodwill Goodwill	4400000
CY2020Q4	us-gaap	Goodwill Goodwill	2900000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-466000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-472000
CY2021Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1236000
CY2020Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1592000
CY2020Q4	ionm	Accrued Salaries And Benefits AccruedSalariesAndBenefits	1163000
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	406000
CY2020Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	116000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	2194000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	2871000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	13684000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	6351000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	515000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4100000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13169000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2251000
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1700000
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.00
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	275000
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.55
CY2021Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P48M
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	180000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12918866
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11275788
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	180000000
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	ionm	Shares Issued During Period New Issues Fractional Shares SharesIssuedDuringPeriodNewIssuesFractionalShares	0
CY2020Q2	ionm	Share Issuance Authorized Amount ShareIssuanceAuthorizedAmount	300000
CY2020Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.05
CY2020Q2	ionm	Number Of Common Stock Issued Per Unit NumberOfCommonStockIssuedPerUnit	1
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.65
CY2020Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	102000
CY2020Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	25185
CY2020Q3	ionm	Number Of Surgeons Who Are Majority Owners NumberOfSurgeonsWhoAreMajorityOwners	2
CY2020Q3	ionm	Shares Issued On Settlement Of Accounts Payable SharesIssuedOnSettlementOfAccountsPayable	10000
CY2020Q3	ionm	Accounts Payable Settled On Issuance Of Common Stock AccountsPayableSettledOnIssuanceOfCommonStock	40000
CY2020Q4	ionm	Number Of Units Issued NumberOfUnitsIssued	3271541
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.20
CY2020Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9500000
CY2020Q4	ionm	Number Of Common Stock Issued Per Unit NumberOfCommonStockIssuedPerUnit	1
CY2020Q4	ionm	Number Of Warrants Issued Per Unit NumberOfWarrantsIssuedPerUnit	1
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.90
CY2020Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.004
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.009
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.004
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.025
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.91
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.37
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.91
CY2020Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3271541
CY2020Q4	ionm	Number Of Units Issued NumberOfUnitsIssued	3271541
CY2020Q4	ionm	Number Of Management Members Who Participated In Financing NumberOfManagementMembersWhoParticipatedInFinancing	3
CY2020Q4	ionm	Number Of Independent Members Who Participated In Financing NumberOfIndependentMembersWhoParticipatedInFinancing	2
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	156032
CY2021Q2	us-gaap	Share Price SharePrice	4.00
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	909262
CY2021Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.25
CY2021Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4750000
CY2021Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	435000
CY2021Q4	us-gaap	Share Price SharePrice	6.19
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	60000
CY2021	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	13384
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.07
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1400000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	548000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1400000
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	474546
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y9M18D
CY2019Q4	ionm	Derivative Liability Fair Value Of Stock Option DerivativeLiabilityFairValueOfStockOption	66000
CY2020	ionm	Gain Loss On Revaluation Of Stock Option GainLossOnRevaluationOfStockOption	-50000
CY2020Q4	ionm	Derivative Liability Fair Value Of Stock Option DerivativeLiabilityFairValueOfStockOption	16000
CY2021	ionm	Gain Loss On Revaluation Of Stock Option GainLossOnRevaluationOfStockOption	-9000
CY2021Q4	ionm	Derivative Liability Fair Value Of Stock Option DerivativeLiabilityFairValueOfStockOption	25000
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	78551
CY2020	ionm	Class Of Warrant Or Right Convertible Debt Warrants Issued ClassOfWarrantOrRightConvertibleDebtWarrantsIssued	302322
CY2020	ionm	Class Of Warrant Or Right Equity Financing Warrants Issued ClassOfWarrantOrRightEquityFinancingWarrantsIssued	3284133
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3665006
CY2021	ionm	Debenture Warrants Issued DebentureWarrantsIssued	275000
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3940006
CY2020	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	284167
CY2020	ionm	Finders Fee Warrants Issued FindersFeeWarrantsIssued	18155
CY2020Q2	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	12592
CY2020Q4	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	3271541
CY2021	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	275000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2756000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15036000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11725422
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7246625
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.07
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2756000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15036000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11725422
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7246625
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.07
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	30000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	30000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-707000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1825000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-152000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-360000
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-859000
CY2020	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-2185000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-829000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2185000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	185000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	219000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1977000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2286000
CY2021Q4	ionm	Deferred Tax Liabilities Equity Method Investments DeferredTaxLiabilitiesEquityMethodInvestments	149000
CY2020Q4	ionm	Deferred Tax Liabilities Equity Method Investments DeferredTaxLiabilitiesEquityMethodInvestments	187000
CY2021Q4	ionm	Deferred Tax Liabilities Accrual To Cash Adjustment DeferredTaxLiabilitiesAccrualToCashAdjustment	7549000
CY2020Q4	ionm	Deferred Tax Liabilities Accrual To Cash Adjustment DeferredTaxLiabilitiesAccrualToCashAdjustment	4368000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5762000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2211000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	34000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	10000
CY2021Q4	ionm	Deferred Tax Assets Debt Issuance Costs DeferredTaxAssetsDebtIssuanceCosts	20000
CY2020Q4	ionm	Deferred Tax Assets Debt Issuance Costs DeferredTaxAssetsDebtIssuanceCosts	32000
CY2021Q4	ionm	Deferred Tax Liabilities Accretion Expense DeferredTaxLiabilitiesAccretionExpense	443000
CY2020Q4	ionm	Deferred Tax Liabilities Accretion Expense DeferredTaxLiabilitiesAccretionExpense	344000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.126
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1194000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.231
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.126
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.231
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	601000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	599000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.028
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.044
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.008
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.009
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.137
CY2021	ionm	Effective Income Tax Rate Reconciliation Provision To Return Adjustment And Other Percent EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentAndOtherPercent	-0.023
CY2020	ionm	Effective Income Tax Rate Reconciliation Provision To Return Adjustment And Other Percent EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentAndOtherPercent	0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.038
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.004
CY2021	ionm	Effective Income Tax Rate Reconciliation Net Operating Loss Carryback Difference Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackDifferencePercent	-0.014
CY2020	ionm	Effective Income Tax Rate Reconciliation Net Operating Loss Carryback Difference Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackDifferencePercent	0.003
CY2019Q4	us-gaap	Equity Method Investments EquityMethodInvestments	2360000
CY2020	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	558000
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	608000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	225000
CY2021	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	308000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	525000
CY2021	ionm	Defined Contribution Plan Threshold Service Period DefinedContributionPlanThresholdServicePeriod	P6M
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.060
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	467000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	409000
CY2021Q4	ionm	Revenue Revenue Adjustments From Contract With Customer Excluding Assessed Tax RevenueRevenueAdjustmentsFromContractWithCustomerExcludingAssessedTax	9659000
CY2021Q3	ionm	Revenue Revenue Adjustments From Contract With Customer Excluding Assessed Tax RevenueRevenueAdjustmentsFromContractWithCustomerExcludingAssessedTax	8546000
CY2021Q2	ionm	Revenue Revenue Adjustments From Contract With Customer Excluding Assessed Tax RevenueRevenueAdjustmentsFromContractWithCustomerExcludingAssessedTax	6222000
CY2021Q1	ionm	Revenue Revenue Adjustments From Contract With Customer Excluding Assessed Tax RevenueRevenueAdjustmentsFromContractWithCustomerExcludingAssessedTax	4765000
CY2021Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-395000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	249000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1781000
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1658000
CY2020Q4	ionm	Revenue Revenue Adjustments From Contract With Customer Excluding Assessed Tax RevenueRevenueAdjustmentsFromContractWithCustomerExcludingAssessedTax	5964000
CY2020Q3	ionm	Revenue Revenue Adjustments From Contract With Customer Excluding Assessed Tax RevenueRevenueAdjustmentsFromContractWithCustomerExcludingAssessedTax	3963000
CY2020Q2	ionm	Revenue Revenue Adjustments From Contract With Customer Excluding Assessed Tax RevenueRevenueAdjustmentsFromContractWithCustomerExcludingAssessedTax	-10736000
CY2020Q1	ionm	Revenue Revenue Adjustments From Contract With Customer Excluding Assessed Tax RevenueRevenueAdjustmentsFromContractWithCustomerExcludingAssessedTax	4333000
CY2020Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-114000
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1344000
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15284000
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-479000
CY2021	dei	Auditor Firm AuditorFirmId	23

Files In Submission

Name	View Source	Status
0001558370-22-003471-index-headers.html	Edgar Link	pending
0001558370-22-003471-index.html	Edgar Link	pending
0001558370-22-003471.txt	Edgar Link	pending
0001558370-22-003471-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ionm-20211231.xsd	Edgar Link	pending
ionm-20211231x10k.htm	Edgar Link	pending
ionm-20211231x10k001.jpg	Edgar Link	pending
ionm-20211231x10k002.jpg	Edgar Link	pending
ionm-20211231x10k003.jpg	Edgar Link	pending
ionm-20211231x10k004.jpg	Edgar Link	pending
ionm-20211231x10k005.jpg	Edgar Link	pending
ionm-20211231x10k006.jpg	Edgar Link	pending
ionm-20211231x10k_htm.xml	Edgar Link	completed
ionm-20211231xex31d1.htm	Edgar Link	pending
ionm-20211231xex31d2.htm	Edgar Link	pending
ionm-20211231xex32.htm	Edgar Link	pending
ionm-20211231xex4d1.htm	Edgar Link	pending
ionm-20211231_cal.xml	Edgar Link	unprocessable
ionm-20211231_def.xml	Edgar Link	unprocessable
ionm-20211231_lab.xml	Edgar Link	unprocessable
ionm-20211231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IONM
Assure Holdings Corp. Stock $ionm

2021 Q4 Form 10-K Financial Statement

#000155837022003471 Filed on March 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IONM Assure Holdings Corp. Stock $ionm

2021 Q4 Form 10-K Financial Statement

#000155837022003471 Filed on March 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IONM
Assure Holdings Corp. Stock $ionm